sherlock, this my not be exactly what you are look
Post# of 151114

The March 2, 2020 announcement includes the following with regard to the microenvironment:
Quote:
Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, “Patients continue to be actively enrolled in this trial based on the expression of CCR5 on lymphocytes and macrophages in the tumor microenvironment. The proposed mechanism of action (MOA) consisting of inhibition of Tregs and repolarization of macrophages has demonstrated a predictable, sustained response that has reduced the size of primary and metastatic tumors and reduced circulating tumor cells in all patients tested so far.”
https://www.globenewswire.com/news-release/20...in-it.html

